Nyxoah S.A. (NYXH)
$9.6932
-0.31 (-3.07%)
Rating:
Recommendation:
-
Symbol | NYXH |
---|---|
Price | $9.6932 |
Beta | 0.000 |
Volume Avg. | 0.01M |
Market Cap | 257.316M |
Shares () | - |
52 Week Range | 7.46-34.2 |
1y Target Est | - |
DCF Unlevered | NYXH DCF -> | |
---|---|---|
DCF Levered | NYXH LDCF -> | |
ROE | -21.25% | Sell |
ROA | -14.56% | Sell |
Operating Margin | - | |
Debt / Equity | 20.71% | Neutral |
P/E | - | |
P/B | 1.54 | Strong Buy |
Latest NYXH news
About
Download (Excel)Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.